This is a proposal to designate the Behavioral Pharmacology Research Unit of the Department of Psychiatry and Behavioral Sciences of The Johns Hopkins University School of Medicine as a drug abuse Treatment Research Center. This Center will serve as an institutional, regional, and national resource concerning drug abuse treatment and concerning drug abuse treatment research, and will serve as a major site of scientific research on drug abuse and drug abuse treatment. The Center program will consist of three major elements: (1) clinical research directly supported by Center funds; (2) research and training activities supported through other funding sources, but affiliated with the Center; and (3) core support resources provided by the Center and used to facilitate and enhance both of the preceding elements. The individual research projects in the Center represent a coordinated program of clinical research involving the active participation and collaboration of all of the major substance abuse treatment programs at this institution. Within the Department's methadone maintenance program we will study the prevalence of psychiatric and substance abuse diagnoses and family histories, compare the detection rates of different diagnostic instruments, evaluate the relation of these patient characteristics to treatment response, and test the efficacy of specific pharmacological (antidepressant medication) and behavioral (contingency management) treatments for those patients diagnosed with depression or antisocial personality, respectively. Within the Department's alcoholism treatment programs we will study the prevalence of polydrug abuse and the diagnostic characterization of polydrug abusers, we will test the feasibility of family therapy with these individuals, and we will assess the efficacy of cognitive behavioral treatment of depression and its impact upon polydrug abuse. We will establish a specialty cocaine abuse outpatient treatment research clinic and, in collaboration with the Department of Medicine's inpatient detoxification Center for Chemical Dependency, will characterize the effects of cocaine abstinence/withdrawal and will conduct controlled clinical trials of pharmacological agents of potential utility in cocaine abuse treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA005273-05
Application #
3105404
Study Section
Special Emphasis Panel (SRCD (41))
Project Start
1988-09-30
Project End
1993-08-31
Budget Start
1992-09-01
Budget End
1993-08-31
Support Year
5
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Peirce, Jessica M; Kindbom, Kori A; Waesche, Matthew C et al. (2008) Posttraumatic stress disorder, gender, and problem profiles in substance dependent patients. Subst Use Misuse 43:596-611
Burke, Christopher K; Peirce, Jessica M; Kidorf, Michael S et al. (2008) Sleep problems reported by patients entering opioid agonist treatment. J Subst Abuse Treat 35:328-33
Wedam, Erich F; Bigelow, George E; Johnson, Rolley E et al. (2007) QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 167:2469-75
Sigmon, Stacey C (2007) Investigating the pharmacological and nonpharmacological factors that modulate drug reinforcement. Exp Clin Psychopharmacol 15:1-20
Carroll, C Patrick; Kidorf, Michael; Strain, Eric C et al. (2007) Comparison of demographic and clinical characteristics between opioid-dependent individuals admitted to a community-based treatment setting and those enrolled in a research-based treatment setting. J Subst Abuse Treat 33:355-61
Lott, David C; Strain, Eric C; Brooner, Robert K et al. (2006) HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone. J Subst Abuse Treat 31:187-94
Sigmon, Stacey C; Moody, David E; Nuwayser, Elie S et al. (2006) An injection depot formulation of buprenorphine: extended bio-delivery and effects. Addiction 101:420-32
Jones, Hendree E; Fitzgerald, Heather; Johnson, Rolley E (2005) Males and females differ in response to opioid agonist medications. Am J Addict 14:223-33
Lofwall, Michelle R; Brooner, Robert K; Bigelow, George E et al. (2005) Characteristics of older opioid maintenance patients. J Subst Abuse Treat 28:265-72
Disney, Elizabeth R; Kidorf, Michael; King, Van L et al. (2005) Prevalence and correlates of cocaine physical dependence subtypes using the DSM-IV in outpatients receiving opioid agonist medication. Drug Alcohol Depend 79:23-32

Showing the most recent 10 out of 44 publications